OnKure Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines targeting biologically validated drivers of cancer underserved by available therapies, particularly oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα); its lead product candidate is OKI-219, a selective PI3Kα H1047R mutant inhibitor in Phase 1 PIKture-01 trial for advanced solid tumors including breast cancer, with dose escalation completed and triplet combination arms enrolling; the pipeline also includes a PI3Kα PAN mutant selective inhibitor program at candidate selection and a PI3Kα E542K/E545K mutant selective inhibitor program in active discovery, all targeting breast cancer and solid tumors. Founded in 2011 and headquartered in Boulder, Colorado, the company employs a structure-based drug design platform to optimize tolerability and efficacy across its oncology portfolio. In October 2024, OnKure completed a merger with Reneo Pharmaceuticals, Inc. and a concurrent $65 million private placement with investors including Acorn Bioventures, Cormorant Asset Management, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Surveyor Capital, and Vestal Point Capital, providing a cash runway into Q4 2026 to support multiple clinical readouts.
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
OnKure Therapeutics Reports First Quarter 2026 Financial Results
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Given Consensus Rating of “Hold” by Analysts
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
OnKure Therapeutics to Participate in Upcoming Investor Conferences
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
OnKure Announces New Date for Upcoming Investor Call
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million